Home > Boards > US OTC > Medical - Drugs >

Addex Therapeutics (ADDXF)

Add ADDXF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/18/2017 9:33:53 AM - Followers: 2 - Board type: Free - Posts Today: 0

Addex Pharmaceuticals (ADDXF on the US Pinks and ADXN in Switzerland) discovers and develops allosteric modulators for human health. The company uses its proprietary discovery platform to target cell surface receptors that are recognized as having therapeutic potential for treating diseases of the central nervous system, metabolic disorders or inflammation.

Best overview of the company's business is this presentation by the new CEO from September 27, 2011: 

Liquidity on US Pinks is near zero -- this company trades best on SWX (Swiss) as "ADXN" or in Germany as "APE" (also pretty bad volume)


Addex Pharmaceuticals discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant  (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and, ADX71149(mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals, Inc., to treat schizophrenia. Another partner, Merck & Co., Inc., is developing mGluR4 PAM for Parkinson's disease. Addex also is advancing several preclinical programs including: mGluR2 NAM for treating Alzheimer's disease and depression; GLP-1R PAM for type 2 diabetes; FSHR NAM for endometriosis and benign prostatic hyperplasia; and GABA-BR PAM for chronic pain, urinary incontinence and other disorders. In addition, Addex has discovery programs to identify allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and Huntington's diseases); TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g. rheumatoid arthritis); and, interleukin receptor family, such as IL1R1 NAM for gout and type II diabetes.

About Addex

Originally conceived as a specialty pharma company focused on addiction, Addex was founded by pharmaceutical industry researchers with €10 million from top European venture capital investors in 2002.  While trying to discover a  new drug to treat addiction, the Addex researchers developed a scalable process for discovering drug-like allosteric modulators. They quickly recognized that this innovation could become a discovery platform that was much more broadly applicable than the company's original business plan had envisioned. Therefore, in 2003, the management adapted and re-focused Addex on industrializing the allosteric modulator discovery and development process.

Although a handful of allosteric modulators have been discovered and are now marketed drugs, they were identified by serendipity. Addex is the first company to focus on industrializing the process of finding and developing allosteric modulators. In order to leverage and build upon its first mover advantage, the company has assembled a team of drug developers with significant pharmaceutical industry experience, including chemists, molecular biologists, biochemists, veterinarians, physicians and others. Advised by some of the world's leading researchers, the team has focused not only on building knowledge of allosteric modulation but also generated a tailored allostery-biased library of over 70,000 compounds as well as proprietary high-throughput biological assays that allow detection, optimization and confirmation of the mechanism of action for allosteric compounds.

Building on these internally discovered tools, Addex has grown into a fully integrated pharmaceutical discovery and development company with significant clinical development capabilities and a diverse pipeline of proprietary compounds that address a broad range of major diseases. Because the allosteric approach is well differentiated, many of the therapeutic targets Addex is pursuing are clinically validated, thereby reducing the risk profile of its products. Addex has a growing portfolio of patents and patent applications covering the composition of matter and methods of use for its allosteric modulators.

Addex has raised a total of CHF 263 Million to date. For more details see our funding history.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#43   Van Leeuwenhoeck Issues Initiation of Coverage Research Report tykundegex 10/18/17 09:33:53 AM
#42   Addex Awarded $5.3 Million Grant from US National tykundegex 10/18/17 09:21:16 AM
#41   IMO, Addex has a decent possibility of a tykundegex 06/08/16 03:35:22 PM
#39   Orphan designation granted for Dipraglurant! Next up, tykundegex 01/04/16 08:37:58 PM
#38   Shares up a little on 15x volume because tykundegex 08/14/15 09:33:18 AM
#37   Addex up 20% on high volume, but no tykundegex 01/06/15 10:13:09 AM
#36   Turns out all that buying was some of tykundegex 07/09/14 10:15:25 AM
#35   3 days in a row with way over tykundegex 07/03/14 02:56:07 PM
#34   whoa, something's up. 15x volume, up almost tykundegex 07/02/14 08:34:34 AM
#33   The news goes from bad to worse with tykundegex 02/07/14 02:14:36 PM
#32   Burn rate is 20M per year, where is 68-Tele 05/08/13 01:27:23 PM
#31   Addex to cut costs, focus R&D, and seek US-listing! tykundegex 02/07/13 05:19:50 AM
#30   The good news just keeps pouring in: tykundegex 11/05/12 11:29:36 AM
#29   Addex Reports ADX71441 Reduces Alcohol Intake in a tykundegex 10/29/12 09:40:41 AM
#28   Article about PD-related diskinesia and mGluR5 from the MJFF: tykundegex 10/11/12 04:25:25 AM
#27   Misc analyst quotes about Addex on The Life tykundegex 10/03/12 07:41:32 AM
#26   Sorry, that woule be August 2013. tykundegex 08/02/12 06:36:01 AM
#25   Addex Partner to Initiate Phase 2 Clinical Trial tykundegex 06/05/12 06:18:51 AM
#24   Up 92% in Zurich today. But tykundegex 03/22/12 08:35:17 AM
#23   This company has blockbuster potential folks -- a tykundegex 03/22/12 05:08:47 AM
#22   Awesome news!!! Addex Reports Positive Top Line tykundegex 03/21/12 01:44:38 PM
#21   Addex changes name to Addex Therapeutics tykundegex 03/21/12 05:04:18 AM
#20   Previously confidential but newly published white paper on tykundegex 03/15/12 06:03:13 AM
#19   Coverage by Ladenburg Thalmann: BUY with target price tykundegex 03/07/12 01:12:10 PM
#18   2012 Addex Corporate Presentation tykundegex 01/10/12 06:18:05 AM
#17   Great overview of the company - CEO presenstaion tykundegex 10/21/11 11:47:28 AM
#16   Article from Sep 5: tykundegex 10/04/11 11:14:52 AM
#15   Addex to Present Progress on Multiple Allosteric Modulator tykundegex 10/04/11 03:55:40 AM
#14   Maybe, since the new CEO has an entirely tykundegex 09/05/11 04:33:49 AM
#13   News: Addex Regains Rights to Parkinson’s Drug Candidates tykundegex 09/05/11 04:32:30 AM
#12   Looks like the CEO was granted rights/options representing tykundegex 08/22/11 03:20:29 AM
#11   Corporate Presentation from Aug 5 tykundegex 08/19/11 06:15:55 AM
#10   Insider: Buying by a executive director / management: tykundegex 08/19/11 06:08:11 AM
#9   New Edison report out (after CEO hire): tykundegex 08/17/11 06:20:35 AM
#8   Addex H1 results tykundegex 08/15/11 06:07:04 AM
#7   Coverage of Addex by Edison from June tykundegex 08/15/11 06:04:35 AM
#6   Corporate Presentation from Aug 5 tykundegex 08/15/11 05:55:19 AM
#5   News: Addex Pharmaceuticals Appoints Dr Bharatt Chowrira as CEO tykundegex 08/15/11 04:46:29 AM
#4   Board just created today. I have been tykundegex 07/14/11 06:49:12 AM
#3   Article in Geneva-based Le Temps newspaper about restructuring: tykundegex 07/14/11 06:45:20 AM
#2   Selling non-executive director: 5000 on 4 July tykundegex 07/14/11 06:25:14 AM
#1   Selling by non-executive director: 5000 on 11 July tykundegex 07/14/11 06:21:24 AM